Literature DB >> 28410569

Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.

Rhonda D Szczesniak1,2,3, Dan Li4, Weiji Su5, Cole Brokamp1, John Pestian6,3, Michael Seid2,7,3, John P Clancy2,3.   

Abstract

RATIONALE: Individuals with cystic fibrosis are at risk for prolonged drops in lung function, clinically termed rapid decline, during discreet periods of the disease.
OBJECTIVES: To identify phenotypes of rapid pulmonary decline and determine how these phenotypes are related to patient characteristics.
METHODS: A longitudinal cohort study of patients with cystic fibrosis aged 6-21 years was conducted using the Cystic Fibrosis Foundation Patient Registry. A statistical approach for clustering longitudinal profiles, sparse functional principal components analysis, was used to classify patients into distinct phenotypes by evaluating trajectories of FEV1 decline. Phenotypes were compared with respect to baseline and mortality characteristics.
MEASUREMENTS AND MAIN RESULTS: Three distinct phenotypes of rapid decline were identified, corresponding to early, middle, and late timing of maximal FEV1 loss, in the overall cohort (n = 18,387). The majority of variation (first functional principal component, 94%) among patient profiles was characterized by differences in mean longitudinal FEV1 trajectories. Average degree of rapid decline was similar among phenotypes (roughly -3% predicted/yr); however, average timing differed, with early, middle, and late phenotypes experiencing rapid decline at 12.9, 16.3, and 18.5 years of age, respectively. Individuals with the late phenotype had the highest initial FEV1 but experienced the greatest loss of lung function. The early phenotype was more likely to have respiratory infections and acute exacerbations at baseline or to develop them subsequently, compared with other phenotypes.
CONCLUSIONS: By identifying phenotypes and associated risk factors, timing of interventions may be more precisely targeted for subgroups at highest risk of lung function loss.

Entities:  

Keywords:  cluster analysis; epidemiology; functional data analysis; nonlinear trajectories; pulmonary function

Mesh:

Year:  2017        PMID: 28410569      PMCID: PMC5564675          DOI: 10.1164/rccm.201612-2574OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  26 in total

1.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

2.  Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Authors:  Gregory S Sawicki; James E Signorovitch; Jie Zhang; Dominick Latremouille-Viau; Markus von Wartburg; Eric Q Wu; Lizheng Shi
Journal:  Pediatr Pulmonol       Date:  2011-08-03

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Longitudinal Patterns of Glycemic Control and Blood Pressure in Pregnant Women with Type 1 Diabetes Mellitus: Phenotypes from Functional Data Analysis.

Authors:  Rhonda D Szczesniak; Dan Li; Leo L Duan; Mekibib Altaye; Menachem Miodovnik; Jane C Khoury
Journal:  Am J Perinatol       Date:  2016-08-04       Impact factor: 1.862

5.  Aortopulmonary collateral flow in cystic fibrosis assessed with phase-contrast MRI.

Authors:  Robert Fleck; Gary McPhail; Rhonda Szczesniak; Joshua Knowlton; Rupa Radhakrishnan; John Clancy; Raouf Amin
Journal:  Pediatr Radiol       Date:  2013-05-16

6.  Lung transplantation and survival in children with cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; David R Cox; Barbara C Cahill
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

7.  Cluster analysis and clinical asthma phenotypes.

Authors:  Pranab Haldar; Ian D Pavord; Ruth H Green; Dominic E Shaw; Michael A Berry; Michael Thomas; Christopher E Brightling; Andrew J Wardlaw
Journal:  Am J Respir Crit Care Med       Date:  2008-05-14       Impact factor: 21.405

8.  A semiparametric approach to estimate rapid lung function decline in cystic fibrosis.

Authors:  Rhonda D Szczesniak; Gary L McPhail; Leo L Duan; Maurizio Macaluso; Raouf S Amin; John P Clancy
Journal:  Ann Epidemiol       Date:  2013-10-05       Impact factor: 3.797

9.  A comparison of change point models with application to longitudinal lung function measurements in children with cystic fibrosis.

Authors:  Angela Moss; E Juarez-Colunga; Farouk Nathoo; Brandie Wagner; Scott Sagel
Journal:  Stat Med       Date:  2016-01-05       Impact factor: 2.373

10.  Shape information from glucose curves: functional data analysis compared with traditional summary measures.

Authors:  Kathrine Frey Frøslie; Jo Røislien; Elisabeth Qvigstad; Kristin Godang; Jens Bollerslev; Nanna Voldner; Tore Henriksen; Marit B Veierød
Journal:  BMC Med Res Methodol       Date:  2013-01-17       Impact factor: 4.615

View more
  17 in total

1.  SPLUNC1 Loses Its Antimicrobial Activity in Acidic Cystic Fibrosis Airway Secretions.

Authors:  Saira Ahmad; Rodney C Gilmore; Neil E Alexis; Robert Tarran
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

2.  Joint hierarchical Gaussian process model with application to personalized prediction in medical monitoring.

Authors:  Leo L Duan; Xia Wang; John P Clancy; Rhonda D Szczesniak
Journal:  Stat (Int Stat Inst)       Date:  2018-03-04

3.  Early Detection of Rapid Cystic Fibrosis Disease Progression Tailored to Point of Care: A Proof-of-Principle Study.

Authors:  Rhonda Szczesniak; Cole Brokamp; Weiji Su; Gary L McPhail; John Pestian; John P Clancy
Journal:  Health Innov Point Care Conf       Date:  2017-12-21

4.  Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure.

Authors:  Kiera H Harwood; Rachel M McQuade; Andrew Jarnicki; Elena K Schneider-Futschik
Journal:  ACS Pharmacol Transl Sci       Date:  2022-06-10

5.  Sleep-disordered breathing in cystic fibrosis.

Authors:  Aarti Shakkottai; Samya Z Nasr; Fauziya Hassan; Sanaya Irani; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med       Date:  2020-06-05       Impact factor: 3.492

6.  Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation.

Authors:  Emrah Gecili; Weiji Su; Cole Brokamp; Eleni-Rosalina Andrinopoulou; Francis J LaRosa Iii; Teresa Pestian; John P Clancy; George M Solomon; John J Brewington; Rhonda D Szczesniak
Journal:  J Cyst Fibros       Date:  2021-05-03       Impact factor: 5.527

7.  Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients.

Authors:  Douglas J Conrad; Barbara A Bailey; Jon A Hardie; Per S Bakke; Tomas M L Eagan; Bernt B Aarli
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

Review 8.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

9.  Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.

Authors:  J S Guimbellot; A Baines; A Paynter; S L Heltshe; J VanDalfsen; M Jain; S M Rowe; S D Sagel
Journal:  J Cyst Fibros       Date:  2020-11-25       Impact factor: 5.482

10.  An Animated Functional Data Analysis Interface to Cluster Rapid Lung Function Decline and Enhance Center-Level Care in Cystic Fibrosis.

Authors:  Jesse Pratt; Weiji Su; Don Hayes; John P Clancy; Rhonda D Szczesniak
Journal:  J Healthc Eng       Date:  2021-05-10       Impact factor: 2.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.